Department of Gastroenterology, Rizhao Hospital of TCM, Rizhao, China.
Department of General Surgery, People's Hospital of Rizhao, Rizhao, China.
Thorac Cancer. 2021 Mar;12(6):932-940. doi: 10.1111/1759-7714.13860. Epub 2021 Feb 3.
Evidence from previous studies showed that the dysregulation of microRNA (miR) is frequently associated with tumor progression. The aberrant miR-210 expression has been identified in a variety of tumors. However, its biological roles in esophageal squamous cell carcinoma (ESCC) still need further elucidation. Thus, in the current study we explore the roles of miR-210 in ESCC progression. The findings of our study reveal that miR-210 is down-regulated in ESCC, which indicates poor prognosis and aggressive tumor progression. Moreover, miR-210 restoration was found to enhance ESCC viability, invasion, and migration abilities. F-Box only protein 31 (FBXO31) was confirmed to be one of the targets of miR-210 in ESCC cells. Results also revealed that miR-210 played crucial roles in regulating ESCC cell epithelial-mesenchymal transition (EMT) and Wnt/β-catenin signaling. In conclusion, data show that miR-210 serves as an anti-ESCC miR via down-regulation of FBXO31 and regulation of EMT and Wnt signaling, suggesting that the miR-210/FBXO31 axis may function as promising therapeutic targets and effective prognostic markers for ESCC patients.
先前的研究证据表明,microRNA(miR)的失调经常与肿瘤进展有关。在各种肿瘤中已经鉴定出异常的 miR-210 表达。然而,其在食管鳞状细胞癌(ESCC)中的生物学作用仍需要进一步阐明。因此,在本研究中,我们探讨了 miR-210 在 ESCC 进展中的作用。我们的研究结果表明,miR-210 在 ESCC 中下调,这表明预后不良和侵袭性肿瘤进展。此外,发现 miR-210 恢复可增强 ESCC 的活力、侵袭和迁移能力。证实 F-Box 仅蛋白 31(FBXO31)是 ESCC 细胞中 miR-210 的靶标之一。结果还表明,miR-210 在调节 ESCC 细胞上皮-间充质转化(EMT)和 Wnt/β-catenin 信号通路中起着关键作用。总之,数据表明,miR-210 通过下调 FBXO31 以及调节 EMT 和 Wnt 信号来发挥抗 ESCC miR 的作用,表明 miR-210/FBXO31 轴可能是 ESCC 患者有前途的治疗靶点和有效的预后标志物。
Am J Physiol Cell Physiol. 2024-8-1
Biochem Biophys Res Commun. 2022-1-1
Clin J Gastroenterol. 2020-12
Cancers (Basel). 2020-9-7
Acta Biochim Biophys Sin (Shanghai). 2020-8-5
Artif Cells Nanomed Biotechnol. 2020-12
Artif Cells Nanomed Biotechnol. 2019-12
J Gastrointest Cancer. 2020-3